Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 334.50
Bid: 331.50
Ask: 333.00
Change: 6.00 (1.83%)
Spread: 1.50 (0.452%)
Open: 323.00
High: 344.50
Low: 323.00
Prev. Close: 328.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

13 Nov 2019 16:41

RNS Number : 3304T
Oxford Biomedica PLC
13 November 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

OXFORD BIOMEDICA PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

CANACCORD GENUITY GROUP INC

City and country of registered office (if applicable)

VANCOUVER, CANADA

4. Full name of shareholder(s) (if different from 3.)v

Name

DISCRETIONARY CLIENTS

City and country of registered office (if applicable)

As above

5. Date on which the threshold was crossed or reachedvi:

12 NOVEMBER 2019

6. Date on which issuer notified (DD/MM/YYYY):

13 NOVEMBER 2019

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.8183

 

4.8183

76,779,548

Position of previous notification (if

applicable)

5.0670

 

5.0670

 

       

 

 

 

 

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BDFBVT43

N/A

3,699,438

N/A

4.8183

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

3,699,438

4.8183

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

         

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Canaccord Genuity Group Inc.

4.8183

 

4.8183

Canaccord Genuity Wealth Group Holdings Limited

4.8183

 

4.8183

Canaccord Genuity Wealth Group Holdings (Jersey) Limited

4.8183

 

4.8183

Canaccord Genuity Wealth Group Limited

4.8183

 

4.8183

Canaccord Genuity Wealth Limited

0.0017

 

0.0017

Hargreave Hale Ltd

4.8166

 

4.8166

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

BLACKPOOL, ENGLAND

Date of completion

13 NOVEMBER 2019

 

Contact name:

Natalie Walter

Contact telephone number:

01865 783000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUOONRKAAAAAA
Date   Source Headline
5th Dec 201610:25 amRNSFindings Reported by Novartis on CTL-019 at ASH
5th Dec 20169:43 amRNSDirector/PDMR Shareholding
1st Dec 20169:27 amRNSTotal Voting Rights
29th Nov 20167:00 amRNSStrategic Alliance with Orchard Therapeutics
28th Nov 201610:06 amRNSDirector/PDMR Shareholding
8th Nov 20166:28 pmRNSGrant of options (Replacement)
8th Nov 20166:13 pmRNSGrant of options
1st Nov 201610:21 amRNSTotal Voting Rights
25th Oct 20164:40 pmRNSDirector/PDMR Shareholding
10th Oct 20167:21 amRNSPublication of RetinoStat® (OXB-201) Phase I study
6th Oct 20169:24 amRNSHolding(s) in Company
5th Oct 201610:17 amRNSHolding(s) in Company
4th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20168:16 amRNSAdmission to Trading and Total Voting Rights
29th Sep 201612:27 pmRNSResult of General Meeting and Directors Dealing
26th Sep 201611:00 amRNSDirector/PDMR Shareholding
13th Sep 20163:07 pmRNSPublication of Prospectus
13th Sep 20167:01 amRNSFUNDRAISING OF £10 MILLION
13th Sep 20167:00 amRNSINTERIM RESULTS FOR 6 MONTHS ENDED 30 JUNE 2016
1st Sep 201610:47 amRNSTotal Voting Rights
25th Aug 20162:22 pmRNSDirector/PDMR Shareholding
2nd Aug 20164:35 pmRNSPrice Monitoring Extension
2nd Aug 20169:32 amRNSTotal Voting Rights
28th Jul 20167:00 amRNSManufacturing Approvals and Expansion Completed
25th Jul 20169:56 amRNSDirector/PDMR Shareholding
8th Jul 201612:02 pmRNSPrice Monitoring Extension
4th Jul 20169:14 amRNSBlock Listing Return
4th Jul 20169:12 amRNSTotal Voting Rights
28th Jun 20164:40 pmRNSSecond Price Monitoring Extn
28th Jun 20164:35 pmRNSSecond Price Monitoring Extn
28th Jun 201612:07 pmRNSSecond Price Monitoring Extn
28th Jun 201612:02 pmRNSPrice Monitoring Extension
27th Jun 201610:37 amRNSDirector/PDMR Shareholding
22nd Jun 201612:07 pmRNSSecond Price Monitoring Extn
22nd Jun 201612:02 pmRNSPrice Monitoring Extension
16th Jun 20164:40 pmRNSSecond Price Monitoring Extn
16th Jun 20164:35 pmRNSPrice Monitoring Extension
15th Jun 201612:07 pmRNSSecond Price Monitoring Extn
15th Jun 201612:02 pmRNSPrice Monitoring Extension
7th Jun 20161:14 pmRNSOxford BioMedica Annual General Meeting
7th Jun 20167:00 amRNSNew Non-Exclusive LentiVector Licence with MolMed
6th Jun 20163:29 pmRNSOXB to Present at Jefferies Healthcare Conference
2nd Jun 201610:05 amRNSR&D Partnership with Green Cross LabCell
2nd Jun 20169:30 amRNSTotal Voting Rights
24th May 201610:08 amRNSDirector/PDMR Shareholding
18th May 20167:00 amRNSDeferred Bonus Plan and LTIP Option Grants
17th May 20167:00 amRNSOxford BioMedica Appoints Corporate Broker
16th May 20169:23 amRNSDirector/PDMR Shareholding
16th May 20169:16 amRNSDirector/PDMR Shareholding
12th May 20167:00 amRNSOxford BioMedica Board Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.